Patents by Inventor Lars Erichsen

Lars Erichsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions and methods for the treatment of prostate cancer
    Patent number: 8722088
    Abstract: Compositions, kits, and methods are provided directed to the treatment of prostate cancer using a maintenance dose of degarelix or pharmaceutically acceptable salt thereof, an excipient, and a solvent.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: May 13, 2014
    Assignee: Ferring International Center S.A.
    Inventors: Tine Kold Olesen, Lars Erichsen, Per Cantor
  • COMPOSITION FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA
    Publication number: 20120172302
    Abstract: The present disclosure is directed to compositions and kits comprising degarelix or a pharmaceutically acceptable salt thereof for the treatment of benign prostate hyperplasia (BPH), methods for treating BPH, and methods for preparing compositions of degarelix or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 5, 2010
    Publication date: July 5, 2012
    Inventors: Axel Niclas Petri, Lars Erichsen
  • COMPOSITIONS, KITS AND METHODS FOR TREATING BENIGN PROSTATE HYPERPLASIA
    Publication number: 20110039787
    Abstract: The present disclosure is directed to compositions and kits comprising degarelix or a pharmaceutically acceptable salt thereof for the treatment of benign prostate hyperplasia (BPH), methods for treating BPH, and methods for preparing compositions of degarelix or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 2, 2010
    Publication date: February 17, 2011
    Inventors: Axel Niclas Petri, Lars Erichsen
  • PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20100305042
    Abstract: Compositions, kits, and methods are provided directed to the treatment of prostate cancer using a maintenance dose of degarelix or pharmaceutically acceptable salt thereof, an excipient, and a solvent.
    Type: Application
    Filed: April 30, 2010
    Publication date: December 2, 2010
    Inventors: Tine Kold Olesen, Lars Erichsen, Per Cantor